A plain sailing, unambiguous, speedy and error-free methodology was progressed for the quanti iable concurrent estimation of Pibrentasvir and Glecaprevir in conglomerated pharmaceutical dosage form. The contrivance was based on Chromatographic separation of both the drugs in reverse phase mode using C 18 (250 X 4.6 mm), 5µ by utilizing phosphate buffer (pH 4.0) and Methyl alcohol in the ratio of 30:70 v/v was allowed to low through column at a rate of 1.0 ml/min, and the detection wavelength was set at 251 nm. The time of retention was found to be 2.205 min for Glecaprevir and 4.996 min for Pibrentasvir. The dimensionality of Glecaprevir and Pibrentasvir was in linear range with a parametric statistic of 0.999 and 0.999. The acceptance criteria of precision was RSD should be not more than 2.0%, and the method showed precision 0.6 and 0.5 for Glecaprevir and Pibrentasvir, which shows that the method was precise. % Assay was found as 100.83 and 100.23, which show that the method was useful for routine analysis. The total recovery was founded to be100.40% and 100.25% for Glecaprevir and Pibrentasvir. LOD and LOQ for Glecaprevirwas found as 2.98 and 10.00 and LOD and LOQ for Pibrentasvir was found as 3.00 and 9.98. The methodology was assessed by various validation parameters in accordance with ICH Guidelines which indicates the method can be employed for routine quality control analysis.
INTRODUCTION
Glecaprevir mainly acts as hepatitis C Virus nonstructural protein 3/4A protease inhibitor (Babu et al., 2018; GampaVijayKumar and Reddy, 2018; Kumar and Raja, 2018) It is used for the treatment of chronic hepatitis C Infection along Pibrentasvir.
Pibrentasvir acts as NS5A inhibitor anti-viral agent (Sangameshwar et al., 2019; Saradhi et al., 2018; Sreeram and Venkateswarlu, 2018) . The combination of Glecaprevir and Pibrentasvir was being approved by US Food and Drug Administration for hepatitis treatment (Issarani et al., 2013) . The chemical structures of Glecaprevir and Pibrentasvir are shown in Figure 1 and Figure 2 .
MATERIALS AND METHODS

Chemicals and Reagents
Glecaprevir and Pibrentasvir were kindly gifted by Pharmatrain Labs Pvt Ltd, Hyderabad certi ied to contain 99.9% and 99.8% purity respectively. Puri ication was not performed for the gifted samples and are used directly for Analysis. All the solvents utilized in analysis were of HPLC grade. Mavyret Tablets (label claim 100 mg of Glecaprevir and 40 mg of Pibrentasvir) of Abbvie pharma was used in analysis.
Instrument
LC system used consists of Waters HPLC having Empower Software with 2695 separation module having PDA detector with 20 µLinjection capacity. The column used was Xterra C 18 Column, 5µ (250× 4.6 mm) at controlled temperature. Various solvents were tested in order to sort out the simplest conditions for drug separation at a particular time.
Optimized Chromatographic conditions
The mobile phase having phosphate buffer (pH 4.0) and methyl alcohol in the proportions of 30:70 v/v was selected because it was found that it ideally resolve the peaks with retention time (RT) 2.205 min and 4.996 min for Glecaprevir and Pibrentasvir respectively. Isobestic point was determined byperforming the spectroscopic analysis in the range of 200 nm to 390nm. Both the components showed reasonably good response at 251 nm with characteristic peak as shown in the Figure 3 .
Preparation of Phosphate Buffer
Precisely Weigh 1.732g of monobasic potassium phosphate was taken in a 500ml volumetric lask, dissolved and diluted to 500ml with HPLC water and the volume was adjusted to pH 4.0 with Ortho Phosphoric Acid. 
Preparation of Mobile Phase
Accurately measured 300 milli litre (30%) of phosphate Buffer and 700 milli litre of Methanol(70%) were mixed and degassed in inaudible water tub for 10 minutes then iltered through 0.45 μ ilter under vacuum iltration. Diluent was mobile phase.
Standard Solution Preparation
Weigh precisely a quantity which is equivalent to 10 mg of Pibrentasvir and 25 mg of Glecaprevir and dissolve in 25 ml of mobile phase which comprises of Phosphate buffer and methanol. Sonicate the above solution for few minutes until the drug samples dissolves completely and pipette out 3 ml of PibrentasvirandGlecaprevir from standard stock solution into two separate 10ml volumetric lasks and make up the volume to the mark with diluents. Inject 20 μL of the standard, sample into the chromatographic system and measure the areas for glecaprevir and pibrentasvir peaks and calculate the % Assay by using the formulae. The Chromatogram of standard solution was shown in Figure 4 . 
Sample Solution Preparation
Weigh precisely a quantity which is equivalent to 5 mg of Pibrentasvir and 12.5 mg of Glecaprevir and dissolve in 25 ml of mobile phase which comprises of Phosphate buffer and methanol. Sonicate the above solution for few minutes until the drug samples dissolve completely and pipette out 3 ml of Pibrentasvir and Glecaprevir from standard stock solution into two separate 10ml volumetric lasks and make up the volume to the mark with diluents. 
Recovery studies
To analyze the correctness of the sample by the process developed and to study the levels of interference of formulation additives recovery experiments were carried out by standard addition method at various levels. From the overall amount of drug found, recovery was estimated. The results were reported in Table 1 . 
RESULTS AND DISCUSSION
Preparation of Calibration Curves by HPLC
Serial dilutions of Glecaprevir (100-500 µg/ml) and Pibrentasvir (40-200 µg/ml) were prepared using a mobile phase as solvent using 10 ml volumetric lasks. Each drug solution was analyzed by HPLC system, and the chromatograms were recorded. The peak spaces of each drug were calculated and also the individual activity curves were planned against magnitude relation of the area underneath curve and concentration of the drug. The chromatogram reports are shown in Table 2 .
HPLC Method Validation
Method validation was assessed by different parameters, which include linearity, accuracy, Speci icity, precision, the limit of detection, the limit of quantitation in accordance with International Council for Harmonisation guidelines.
Linearity and Range
The one-dimensionality of a technique is its ability to get take a look at results that area unit directly proportional to the sample concentration over a given vary. The peak area and concentration were aforethought to induce atypical standardization plot. The linearity range for Pibrentasvir and Glecaprevir was found to be 40 to 200 μg/ml and 100-500 μg/ml, respectively. The Correlation coeficient value for the calibration plot of Pibrentasvir and Glecaprevir was 0.999; it shows good linearity for both the drugs. The calibration curves were given in Figure 6 and Figure 7 . 
Accuracy
Accuracy was determined by sneakiness of the measured worth to actuality worth for the sample. The percentage recovery of Pibrentasvir was found to be 100.23%, 100.50% and 100.02% for accuracy 50%, 100% and 150% samples respectively. The mean recovery for Pibrentasvir is 100.25. The %RSD of the samples was found to be less than 2, and Glecaprevir was found to be 100.54%, 100.73% and 99.94% for accuracy 50%, 100% and 150% samples respectively. The mean recovery for Glecaprevir is 100.40. The %RSD of the samples was found to be less than 2. Reports of accuracy were given in Table 3 .
Precision
Repeatability studies were studied by a series of measurements are done with pibrentasvir and glecaprevir. Peak area was measured for six replicate injections of both the drugs. % Relative Standard Deviation for the area measured of repeated injections was found to be at intervals the desired range. The reports for precision were given in Table 4 . 
Limit of Detection and Limit of Quanti ication
Robustness and Ruggedness
Robustness and Ruggedness studies were studied by ive replicate injections of Pibrentasvir and Glecaprevir on different days. The acceptance criteria for robustness and ruggedness can be assessed by measuring the percentage relative standard deviation, which should not be of not more than 2%. The reports were tabulated Table 5 in and Table 6 .
Degradation Studies
The International Council for Harmonization (ICH) guideline entitled stability testing of recent pharmaceutical compounds and merchandise needs that stress sampling is dispensed to explain the stability of active pharmaceutical ingredients. The aim of this work was to perform the degradation studies on the Pibrentasvir and Glecaprevir using the developed method.
Hydrolytic degradation under acidic condition
Accurately measure 3 ml of the above solution and add 3 ml of 0.1N HCL. Transfer the above contents into 10 ml volumetric lask. Keep the Volumetric lask at a temperature of 60ºC for one day and neutralization was carried out by 0.1N NaOH. Make up the volume up to 10 ml with diluent and iltration was performed by using whatmann grade ilter paper and the iltrate was stored in vials.
Hydrolytic degradation under alkaline condition
Accurately measure 3 ml of the above solution and add 3 ml of 0.1N NaOH. Transfer the above contents into 10 ml volumetric lask. Keep the Volumetric lask at a temperature of 60ºC for one day and neutralization was carried out by 0.1 N HCL. Make up the volume up to 10 ml with diluent and iltration was performed by using whatmann grade ilter paper and the iltrate was stored in vials.
Oxidative degradation
Accurately measure 3 ml of the above solution and add 1 ml of 30% w/v of Hydrogen peroxide. Transfer the above contents into 10 ml volumetric lask. Keep the Volumetric lask at a temperature of 60ºC for 15 minutes. Make up the volume up to 10 ml with diluent and iltration was performed by using whatmann grade ilter paper and the iltrate was stored in vials.
Thermal-induced degradation
Glecaprevir and Pibrentasvir sample was taken in Petri dish and placed in Hot air oven at 110 0 C for 3 hours. Dilution was performed by adding diluents to the sample and was analyzed by injecting into HPLC. All the results of stability testing were tabulated in Table 7 .
CONCLUSIONS
Several trials were carried out to achieve optimized chromatographic conditions. The initial attempt was to use as much low proportion of organic solvents for the chromatographic separation of the compounds. Usage of binary compound solvents results in enhancement of elution time of each the compounds. The proposed method can be used for acceptable results. The proposed technique is simple, speedy and statistically valid for its accuracy. Hence no interfering peaks were found in the chromatograms shows that anyone excipient is not interfered during the chromatographic separation of both the drugs. 
